A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC
Public ClinicalTrials.gov record NCT07725796. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UGN-501 Administered Intravesically in Adult Participants With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is being conducted to evaluate the safety and tolerability of UGN-501 administered intravesically in adult participants with recurrent non-muscle invasive bladder cancer (NMIBC) and to determine the recommended Phase 2 dose (RP2D).
Study identification
- NCT ID
- NCT07725796
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 30 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 29, 2026
- Primary completion
- Aug 1, 2029
- Completion
- Aug 1, 2029
- Last update posted
- Jul 23, 2026
2026 – 2029
United States locations
- U.S. sites
- 11
- U.S. states
- 8
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| East Valley Urology Center of Arizona | Queen Creek | Arizona | 85140 | — |
| Michael G Oefelein Clinical Trials | Bakersfield | California | 93301 | — |
| Urology Center of Southern California | Murrieta | California | 92563 | — |
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
| Ichan School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| SUNY Upstate Medical University | Syracuse | New York | 13210 | — |
| University of Pennsylvania-Perelman Center for Advanced Medicine | Philadelphia | Pennsylvania | 19104 | — |
| START Carolinas | Myrtle Beach | South Carolina | 29572 | — |
| UPNT Research Institute | Arlington | Texas | 76017 | — |
| Urology Austin | Austin | Texas | 78759 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07725796, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 23, 2026 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07725796 live on ClinicalTrials.gov.